Past studies have also revealed that JQ1 can be used to treat vemurafenib-resistant melanoma cells [18] and that BET inhibitors effectively suppress melanoma progression via the noncanonical NF-κB/SPP1 pathway [19]. Here, NFKB1 is linked to melanoma.